gliomas It is a group of central nervous system tumors that arise from glial cells, the support, nutrition and repair functions of neurons. Approximately. 75% of all gliomas are astrocytomaIncluding the most common – glioblastoma multiforme. It’s a type of brain tumor that’s hard to treat – only half of patients survive a year after diagnosis.
Scientists from the University of Leeds and the University of Surrey have created a special blend of chemicals Fighting mutations in the Hox genes.
People with gliomas have a 5 percent survival rate over five years — a number that hasn’t improved in decades. While we are still in the early stages of the process, our seven-year project offers a glimmer of hope for a solution to the problem of dysregulation of the Hox genes, which is linked to the development of gliomas and other types of cancer, which is proven, the professor said. Hardev Panda from the University of Surrey.
A peptide called HTL-001 It contains short-chain amino acids, which are the building blocks of proteins. Hox genes are responsible for the growth of neurons during embryonic development, but when we are born, they usually stop working. If they are not “operated” correctly, this can lead to the development of cancer. Hox gene dysregulation has long been known to occur in many gliomas.
We urgently need new treatments for these severe brain tumors. Targeting developmental genes such as Hox genes that are turned incorrectly in cancer cells could be a new and effective way to prevent glioblastoma from growing and becoming life-threatening. Susan Short of the University of Leeds, co-author of the research.
Hox . genes remained Associated with many common cancers, from colon, breast, ovary, and cervix to leukemia. Clinical trials of the HTL-001 peptide will soon begin. It is currently being considered for use as an alternative form of treatment for gliomas and other types of cancer.
“Internet Geek. Food Enthusiast. Thinker. Beer Practitioner. Bacon Specialist. Music Addict. Traveler.”